Nitrilase mutant and application thereof in production of D-mandelic acid
By performing site-directed mutation of nitrile hydrolase, a nitrile hydrolase mutant with high activity and tolerance is obtained, which solves the problems of high cost and low substrate tolerance in the prior art, and achieves a high-efficiency and low-cost D- Mandelic acid preparation, suitable for industrial production.
Patent Information
- Application Number
- CN202411313402.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-20
- Publication Date
- 2024-11-08
AI Technical Summary
The existing methods for catalyzed preparation of D-mandelic acid by nitrile hydrolase have high production costs, low substrate tolerance and cumbersome product extraction process, which limits the application of industrial production.
By performing site-directed mutation of nitrile hydrolase, nitrile hydrolase mutants are obtained, mutations of mutation sites including lysine, proline, glycine and isoleucine, improving the activity of enzymes and substrate tolerance, achieving no need for Catalytic reaction of batch feed and organic solvent.
It improves the synthesis efficiency and product purity of D-mandelic acid, reduces production costs, and achieves high yield and high purity D-mandelic acid preparation, which is suitable for industrial applications.
Smart Images

Figure CN118910023A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of genetic engineering, in particular to a nitrilase mutant and application thereof in producing D-mandelic acid. Background Art
[0002] Mandelic acid, also known as mandelic acid, has a chiral carbon atom and two enantiomers, (R) and (S). R-mandelic acid (i.e., D-mandelic acid) is a chemical intermediate with a wide range of uses. It has a wide range of uses in organic synthesis and drug production. It is a commonly used raw material or intermediate in the field of drug synthesis and dyes, such as semi-synthetic penicillin and cephalosporin antibiotics, vasodilators, bactericides, antispasmodics, weight loss drugs, anti-tumor drugs, etc.; it is also used as a bactericide or preservative. In recent years, the demand for R-mandelic acid has increased year by year, and the market potential is huge. It is of great significance to accelerate the preparation and development of R-mandelic acid.
[0003] The preparation methods of D-mandelic acid include asymmetric synthesis, optical isomer separation, and biosynthesis, among which biotransformation is the most ideal method. Most of the synthetic routes of the biotransformation method use mandelonitrile as a substrate, which is converted into D-mandelic acid by nitrilase. For example, the patent with application number 202111620813.7 uses a nitrilase to catalyze the preparation of D-mandelic acid, but in this method, the solvent methyl isobutyl ketone is used in the enzyme catalysis process, which increases the production cost; the patent with application number 200910154484.4 uses nitrilase to catalyze D-mandelonitrile to prepare D-mandelic acid, the substrate concentration tolerance is low, the hydrolysis process adopts a batch feeding method, and no post-processing methods such as product extraction are mentioned, which is not conducive to the application in industrial production; the patent with application number 200910155228.7 uses a resin elution method for product extraction, which is cumbersome and also not suitable for scale-up production.
[0004] In view of this, the present invention is proposed. Summary of the invention
[0005] The object of the present invention is to provide a nitrilase mutant and its application in the production of D-mandelic acid. By performing site-directed mutation on the nitrilase, the activity and tolerance of the obtained nitrilase mutant to the substrate are improved, and no batch addition or other organic solvent is required during the reaction process. The nitrilase mutant of the present invention is used to produce D-mandelic acid, which can improve production efficiency and reduce production costs.
[0006] The present invention is achieved in that:
[0007] The route of synthesizing D-mandelic acid of the present invention is as follows Figure 1 As shown, D-mandelic acid is prepared by converting D-mandelonitrile as a substrate through nitrilase.
[0008] The invention obtains a nitrilase mutant by mutation of wild-type nitrilase by gene site saturation mutagenesis. Specifically, the amino acid sequence of the wild-type nitrilase is shown in SEQ ID NO.1, and the nucleotide sequence is shown in SEQ ID NO.3. The nitrilase mutant is a mutation based on the amino acid sequence shown in SEQ ID NO.1, and the mutation sites include the 132nd, 189th, 196th, and 284th positions.
[0009] Among them, the mutation at position 132 is: lysine mutates to alanine, that is, K132A.
[0010] The mutation at position 189 is: proline mutates to threonine, that is, P189T.
[0011] The mutation at position 196 is: glycine mutates to serine, i.e. G196S.
[0012] The mutation at position 284 is: isoleucine mutates to alanine, i.e. I284A.
[0013] The mutations at positions 132, 189, 196, and 284 can improve the nitrilase activity and substrate tolerance, thereby improving the synthesis efficiency of D-mandelic acid.
[0014] Furthermore, the mutation mode of the nitrilase mutant is a combination of K132A, P189T, G196S and I284A. The amino acid sequence of the nitrilase mutant is shown in SEQ ID NO.2, and the nucleotide sequence is shown in SEQ ID NO.4.
[0015] The related biological materials can be obtained through the above-mentioned nitrilase mutant, which include: an expression cassette containing the above-mentioned nucleic acid molecule; a recombinant vector containing the above-mentioned nucleic acid molecule, or a recombinant vector containing the above-mentioned expression cassette; a recombinant bacterium containing the above-mentioned nucleic acid molecule, or a recombinant bacterium containing the above-mentioned expression cassette, or a recombinant bacterium containing the above-mentioned recombinant vector.
[0016] In some embodiments, the method for constructing a recombinant bacterium expressing the above-mentioned nitrilase mutant comprises: connecting the nucleotide sequence of the nitrilase mutant to an expression vector, then transforming the obtained recombinant vector into a starting strain, culturing the starting strain, and inducing expression of the nitrilase mutant.
[0017] The expression vector and host cell can be selected conventionally in the art. In some embodiments, the expression vector is pET28MA and the starting strain is Escherichia coli. The catalytic activity of the obtained nitrilase mutant is better than that of the original enzyme by inducing protein expression and disrupting cells to obtain a crude enzyme solution using the above method.
[0018] Based on this, the present invention also provides a fermentation agent, the active ingredients of which include the above-mentioned nitrilase mutant and / or biological material.
[0019] At the same time, the present invention also provides a method for producing D-mandelic acid, comprising: adding a nitrilase mutant to a conversion system for reaction, and then obtaining D-mandelic acid after separation, filtration, concentration, crystallization and drying; wherein the conversion system comprises D,L-mandelonitrile, sodium hydroxide and sodium phosphate buffer.
[0020] In some embodiments, during the production of D-mandelic acid, the addition amount of the nitrilase mutant is 1.2-1.6 g / 10 mL D,L-mandelonitrile; and the concentration of D,L-mandelonitrile in the conversion system is 400 mM-1000 mM.
[0021] In order to obtain higher yield and purity, the inventors further optimized the reaction conditions and found that when the substrate concentration was 400mM-1000mM and the mass volume ratio of the nitrilase mutant to the substrate was 1.2-1.6:10g / mL, the yield could reach more than 90% and the purity could reach more than 99%.
[0022] In some embodiments, the reaction conditions of the nitrilase mutant in the reaction system are: pH 7.5-8.0, temperature 25° C.-35° C., and shaking speed 200 rpm-300 rpm.
[0023] In some embodiments, the nitrilase mutant is obtained by expressing the recombinant bacteria, including: inducing and culturing the constructed recombinant bacteria, and then crushing and centrifuging and collecting the supernatant to obtain the nitrilase mutant enzyme solution.
[0024] Specifically, the constructed recombinant bacteria were inoculated into LB medium containing kanamycin, cultured at 30°C-40°C and 200 rpm for 10 h, and then inoculated into a shake flask containing TB medium at a 2%-3% inoculum; cultured in a shaker at 30°C-40°C and 200 rpm, and when the OD of the culture solution reached 600nm When the p-value reaches 0.6 0.8, 0.2 mM IPTG is added, and the mixture is induced at 20°C-25°C and 180 rpm for 12 hours; the supernatant bacteria are collected by centrifugation at 4°C-5°C and 8000 rpm for 10 minutes or 6000 rpm for 20 minutes, and the supernatant bacteria are washed twice with 100 mM sodium phosphate buffer with a pH of 7.0; the obtained bacteria are suspended with 100 mM sodium phosphate buffer with a pH of 7.0, ultrasonically broken in an ice bath, and the supernatant is collected by centrifugation to obtain the nitrilase mutant enzyme solution.
[0025] In some embodiments, the method for producing D-mandelic acid can also be: the recombinant bacteria expressing the above-mentioned nitrilase mutant are crushed, and then the supernatant thereof is added to the transformation system for reaction to obtain D-mandelic acid.
[0026] A higher yield and purity can also be obtained by the whole-cell transformation method, in which the mass ratio of substrate to recombinant bacteria is 5:0.021; the reaction conditions are: pH 7.5-8.0, temperature 25°C-35°C, and shaker speed 200-300rpm.
[0027] In some embodiments, after the reaction is completed, the reaction system is sequentially separated, filtered, concentrated, crystallized and dried. Specifically, after the reaction is completed, the temperature is raised to 80°C-90°C for inactivation, then cooled to 40°C-50°C, 100mL of 0.1g / mL diatomaceous earth is added, stirred and washed, and then filtered; the filtered solution is concentrated under reduced pressure at 70°C-80°C to less than 30% of the volume of the reaction system, and then the pH of the concentrated solution is adjusted to pH=1-1.5, stirred and cooled to 5°C-10°C, crystallized and dried.
[0028] The present invention has the following beneficial effects:
[0029] The present invention provides a nitrilase mutant and its application in catalyzing D-mandelic acid. The mutant has high catalytic activity and substrate tolerance, can convert D, L-mandelonitrile to prepare D-mandelic acid, the maximum reaction concentration of the substrate can reach 1M during the reaction, the hydrolysis process does not need to be added in batches, and does not require other organic solvents, and the subsequent processing steps are simple. At the same time, the present invention also optimizes the reaction conditions, the final yield can reach more than 90%, the purity is more than 99%, and the production method of the present invention can improve the generation efficiency of D-mandelic acid and reduce the production cost. Therefore, the nitrilase mutant of the present invention and the method for producing D-mandelic acid have good industrial application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.
[0031] Figure 1 A route map for producing D-mandelic acid according to the present invention;
[0032] Figure 2 The pET-28MA plasmid map constructed in Example 2;
[0033] Figure 3This is the purity test result in Example 3. DETAILED DESCRIPTION
[0034] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0035] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0036] Example 1
[0037] This example is the screening of nitrilase mutants, as follows:
[0038] The wild sequence of nitrilase was modeled according to homology and further modified by gene site saturation mutagenesis. After mutagenesis, a convenient two-step high-throughput screening method based on product formation and pH indicator was combined with HPLC to screen positive mutants.
[0039] After testing by gene site saturation mutagenesis, the nitrilase with the highest activity and tolerance to the substrate was screened out. The nucleotide sequence of the wild-type nitrilase is shown in SEQ ID NO: 3:
[0040] ATGACCATCAATCACCCGCGCTATGTGGTGGCTGCCGTTCAGGCGGCCCCCGTGTTCCTGGACCTCGAAGCAACGGTCACTAAGACCATCGAGCTCATCGAGGAAGCCGCCCGCAACGGTGCCACCTTGATTGCCTTTCCGGAAACCTGGATTCCCGGATACCCGTTGTTTTCCTGGCTCGGCTCGCCGGCTTGGAGTCTGCAGTTTTTTCAGCGCTATCATGACAATTCGCTTGTCATCAACAGCGAGCAATACCGTCTCATCGAACAAGCAGCAGCTCGCAACAAGATCATGGTGGTGCTGGGATTCAGTGAGCGTGACGCCGGCTCGTTGTACATCTCCCAATCGATCATCAACAGCGAAGGGATCACGATTTCCACGCGCCGCAAGCTGAAGCCGACCCATGTCGAAAGGACCGTGTTCGGCGAAGGGGACGGGAGTGACCTCTCTGTTCACGAAACGGAGCTGGGCCGTGTAGGCGCACTATGCTGCTGGGAACATCTGCAACCGCTTACTCGGTACGCGATGTTCGCGCAGAATGAACAGGTGCACATCGGCGCGTGGCCCAGTTTCTCCCTCTATGCCGGCGCAGCCTATACGCTCGGCCCGGAAGTCAATACGGCCGTCAGCCAGATCTATGCTGTCGAGGGCCAGTGCTTCGTCGTAGCACCCAGCGCTGTCGTGTCCGAACAGATGATCGAGCTTCTGTGCTCGACGCCTGAGCACCACGCGCTGCTGCAAGCGGGCGGCGGCCATGCACGCATCTTCGGGCCGGATGGCCGCTCGCTGGCCGAACCCATACCGGAGAATGTCGAGGGCATTCTCTATGCGGAAATCGATCTGAGCGTGATCAGCCTCGCCAAGGCTGCGGCGGACCCTGCCGGCCACTATTCGCGACCCGACGTCACCAGATTGCTGCTAGACCCCACGCCCAAATCTCGTGTAGTCCATGTCCGGGCGGAACCGGCAGCGCCTGAAATGCAACCGGCAACTGCAGTTGTTCAAGTCGATCAGCCAACCGAGCCGCTCGAGCGCGTCACACCCGCTTAA。
[0041] The mutated nucleotide sequence is shown in SEQ ID NO:4:
[0042] ATGACCATCAATCACCCGCGCTATGTGGTGGCTGCCGTTCAGGCGGCCCCCGTGTTCCTGGACCTCGAAGCAACGGTCACTAAGACCATCGAGCTCATCGAGGAAGCCGCCCGCAACGGTGCCACCTTGATTGCCTTTCCGGAAACCTGGATTCCCGGATACCCGTTGTTTTCCTGGCTCGGCTCGCCGGCTTGGAGTCTGCAGTTTTTTCAGCGCTATCATGACAATTCGCTTGTCATCAACAGCGAGCAATACCGTCTCATCGAACAAGCAGCAGCTCGCAACAAGATCATGGTGGTGCTGGGATTCAGTGAGCGTGACGCCGGCTCGTTGTACATCTCCCAATCGATCATCAACAGCGAAGGGATCACGATTTCCA.
[0043] Example 2
[0044] The construction of the recombinant bacteria expressing the nitrilase mutant of Example 1 and the induction of expression are as follows:
[0045] (1) Vector construction
[0046] The gene sequence shown in SEQ ID NO:4 was inserted into the pET-28b plasmid via EcoRI / HindIII, and the recombinant plasmid vector was transformed into competent cells of Escherichia coli BL21 (DE3) to express the protein, thereby obtaining a recombinant bacterium capable of inducing nitrilase. The plasmid map is shown in FIG. Figure 2 shown.
[0047] (2) Inducible expression of recombinant bacteria
[0048] 1) All recombinant expression plasmids with correct sequences after sequencing verification were heat transformed into competent cells of Escherichia coli BL21 (DE3) to express proteins;
[0049] 2) Add the transformed competent cells to LB medium (containing 100 μg / mL kanamycin) and culture at 37°C with shaking at 220 rpm;
[0050] 3) When the cells reach OD 600nm = 0.6, add IPTG (isopropyl-β-d-thiogalactopyranoside) with a final concentration of 1 mM and continue induction at 16°C for 8-12 h to induce protein expression;
[0051] 4) After the induction was completed, the induced cells were centrifuged at 8,000 rpm for 15 min to collect the cells;
[0052] 5) Subsequently, the collected cells were resuspended in a 20 mM imidazole PBS buffer solution and lysed using an ultrasonic disruptor at low temperature;
[0053] 6) After lysis, collect the cell lysate by centrifugation (12,000 rpm, 30 min);
[0054] 7) Filter the cell supernatant collected by centrifugation through a 0.22 μm cellulose acetate filter, add it to a 5 mL Co-NTA HisTrap affinity chromatography column, and rinse it with PBS (containing 50 mM imidazole) buffer solution to remove some non-specifically bound proteins in the supernatant;
[0055] 8) Finally, the His-tagged target protein was eluted with a PBS solution containing 250 mM imidazole, and the elution volume was about 5 column volumes;
[0056] 9) Collect the eluted liquid at different time periods using EP tubes, analyze the collected components by SDS-PAGE, and verify whether the target gene expresses the target protein in E. coli.
[0057] (3) Inducing enzyme production
[0058] 1) The constructed recombinant bacteria capable of inducing nitrilase were inoculated into LB medium containing kanamycin, cultured at 37° C. and 200 rpm for 10 h, and then inoculated into a shake flask containing TB medium at an inoculum size of 2%;
[0059] 2) Incubate at 37°C, 200 rpm in a shaking incubator until the OD 600nm When the concentration reached 0.6 to 0.8, 0.2 mM IPTG was added and induced at 25 °C and 180 rpm for 12 h;
[0060] 3) Centrifuge at 8000 rpm for 10 min or 6000 rpm for 20 min at 4°C to collect the supernatant, and wash twice with 100 mM sodium phosphate buffer (pH 7.0);
[0061] 4) The obtained bacterial cells were suspended in 100 mM sodium phosphate buffer with a pH of 7.0, and ultrasonically disrupted in an ice bath. The supernatant was collected by centrifugation to obtain a nitrilase mutant enzyme solution.
[0062] Example 3
[0063] This embodiment is a method for producing D-mandelic acid, which is as follows:
[0064] This example was carried out in a 2500 mL three-necked round-bottom flask with a 1000 mL system.
[0065] (1) A reaction mixture containing 950 mL of sodium phosphate buffer (100 mM, pH 8.0) and 5 g of wet cells of Escherichia coli in Example 2 was first incubated at 30° C. for 30 min, and then 50 mL (420 mM) of DL-mandelonitrile was added. The temperature was maintained at 30° C. during the reaction, and the pH of the reaction mixture was maintained between 7.5 and 8.0 by adding 6 M sodium hydroxide. The stirring speed of the reaction was set to 250 rpm. Samples were taken regularly, and the reaction process was monitored by thin layer chromatography (TLC) and high performance liquid chromatography (HPLC).
[0066] (2) Product extraction:
[0067] 1) After the reaction control is completed, heat up to 90℃ for 0.5h to inactivate; cool down to 50℃, add 10g of diatomaceous earth and filter, wash the diatomaceous earth once with 100mL of water and filter.
[0068] 2) Concentrate under reduced pressure at 75°C until the reaction system is about 15%, i.e., 3 times the volume of the raw material, and the concentration is completed.
[0069] 3) Add concentrated hydrochloric acid to the concentrated liquid until the pH is about 1, stir and cool to 10°C, crystallize for 1 hour, and then filter. Rinse the filter cake once with 50 ml of ice water, filter, and obtain a wet product, which is dried at 45°C to obtain the target product.
[0070] After testing, the yield of the target product D-mandelic acid was 59.2 g, the purity was 99.72%, and the yield was 92.8%. Figure 3 shown.
[0071] Example 4
[0072] This embodiment is a method for producing D-mandelic acid, which is as follows:
[0073] This example was carried out in a 4500 mL system: a reaction mixture containing 4000 mL of sodium phosphate buffer (100 mM, pH 8.0) and 56.7 g of wet cells of E. coli in Example 2 was first incubated at 30° C. for 30 min, and then 405 mL of DL-mandelonitrile was added. The temperature was maintained at 30° C. during the reaction, and the pH of the reaction mixture was maintained between 7.5 and 8.0 by adding 6 M sodium hydroxide. The stirring speed of the reaction was set to 250 rpm. Samples were taken regularly, and the reaction process was monitored by thin layer chromatography (TLC) and high performance liquid chromatography (HPLC).
[0074] After the reaction was completed, the temperature was raised to 90°C for 0.5h for inactivation; the temperature was lowered to 50°C, 45g of diatomaceous earth was added for filtration, and the diatomaceous earth was washed twice with 300mL of water and filtered.
[0075] 2) Concentrate under reduced pressure at 75°C until the reaction system is concentrated to about 20%.
[0076] 3) Add concentrated hydrochloric acid to the concentrated liquid until the pH is about 1, stir and cool to 10°C, crystallize for 1 hour, and then filter. Rinse the filter cake once with 150 ml of ice water, filter to obtain a wet product, and dry at 45°C to obtain the target product D-mandelic acid with a yield of 471.5 g, a purity of 99.82%, and a yield of 91.2%.
[0077] Comparative Example 1
[0078] The difference from Example 3 is that the nitrilase mutant in Example 3 is replaced by the wild-type nitrilase, and other synthesis conditions are kept unchanged. The final target product yield and purity results are shown in Table 1:
[0079] Table 1 Product yield and purity of comparative example 1
[0080] Yield % purity% 44.6 61.3
[0081] Experimental example
[0082] In this experiment, based on Example 3, the mutant enzyme solution of nitrilase was used to react with the substrate, the substrate concentration was kept constant and the enzyme dosage was changed, and the effects of different enzyme dosages on the results were compared. The results are shown in Table 2:
[0083] Table 2 Effect of different enzyme amounts on production results
[0084]
[0085]
[0086] When the enzyme dosage is less than 1 g per 10 ml of raw material, the substrate reaction is incomplete, resulting in insufficient yield and product purity. As the amount of enzyme increases, the product conversion rate and purity increase accordingly. When the enzyme dosage reaches more than 1.6 g per 10 ml, there is no significant change in yield and purity.
[0087] On the basis of the above experiments, the amount of enzyme was kept unchanged, the concentration of substrate was changed, and the effects of different substrate concentrations were compared. The results are shown in Table 3:
[0088] Table 3 Effect of different substrate concentrations on production results
[0089] Group Substrate concentration (mM) Yield % purity% 1 350 91.5 99.76 2 550 90.6 99.51 3 750 88.7 98.76 4 950 87.1 96.57 5 1050 79.0 89.80 6 1150 76.7 85.45
[0090] It can be seen from Table 3 that when the substrate concentration reaches above 950 mM, the yield and purity are significantly reduced.
[0091] In order to further determine the appropriate substrate concentration and enzyme amount, when the substrate concentration was above 750 mM, the experimental results of various substrate concentrations and different enzyme amounts were compared. The results are shown in Table 4:
[0092] Table 4 Effects of different substrate concentrations and enzyme dosages on production results
[0093]
[0094]
[0095] It can be seen from Table 4 that: after comparing different substrate concentrations with different enzyme amounts, when the substrate concentration reaches above 1000mM, further increasing the amount of enzyme does not significantly improve the yield and purity. Considering the comprehensive product yield, purity and cost, the best conversion conditions are: substrate concentration 400mM-1000mM, enzyme amount per 10ml substrate maintained at 1.2-1.6, the yield can reach up to more than 90%, and the purity can reach more than 99%.
[0096] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A nitrilase mutant, characterized in that The nitrilase mutant is obtained by mutation based on the amino acid sequence shown in SEQ ID NO.1, and the mutation sites of the nitrilase mutant include: the 132nd, 189th, 196th, and 284th positions.
2. The nitrilase mutant according to claim 1, characterized in that The mutation mode of the nitrilase mutant is a combination of the following (1)-(4): (1) mutating the lysine at position 132 in the amino acid sequence shown in SEQ ID NO.1 to alanine; (2) mutating the proline at position 189 in the amino acid sequence shown in SEQ ID NO.1 to threonine; (3) mutating the glycine at position 196 in the amino acid sequence shown in SEQ ID NO.1 to serine; (4) The isoleucine at position 284 in the amino acid sequence shown in SEQ ID NO.1 is mutated to alanine.
3. The nitrilase mutant according to claim 2, characterized in that The nucleotide sequence of the nitrilase mutant is shown in SEQ ID NO.
4.
4. A biomaterial related to the nitrilase mutant according to any one of claims 1 to 3, characterized in that: Any one of the following (1)-(3): (1) an expression cassette containing the nucleotide sequence of the nitrilase mutant; (2) a recombinant vector containing the nucleotide sequence of the nitrilase mutant, or a recombinant vector containing the expression cassette described in (1); (4) A recombinant bacterium containing the nucleotide sequence of the nitrilase mutant, or a recombinant bacterium containing the expression cassette described in (1), or a recombinant bacterium containing the recombinant vector described in (2).
5. Use of the nitrilase mutant according to any one of claims 1 to 3 or the biomaterial according to claim 4 in the production of D-mandelic acid and its derivatives.
6. A leavening agent, characterized in that The invention comprises the nitrilase mutant according to any one of claims 1 to 3 or the biomaterial according to claim 4.
7. A method for producing D-mandelic acid, characterized in that: include: The nitrilase mutant is added into a transformation system for reaction, and then separated and purified to obtain D-mandelic acid; the transformation system comprises D,L-mandelonitrile, sodium hydroxide and sodium phosphate buffer.
8. The method according to claim 7, characterized in that The addition amount of the nitrilase mutant is 1.2-1.6 g / 10 mL D,L-mandelonitrile; the concentration of D,L-mandelonitrile in the conversion system is 400 mM-1000 mM; Preferably, the reaction conditions are: pH 7.5-8.0, temperature 25°C-35°C, and shaking speed 200-300 rpm.
9. The method according to claim 7, characterized in that: Separation includes: After the reaction is completed, the temperature is raised to 80-90°C for inactivation, then lowered to 40-50°C, 100 mL of 0.1 g / mL diatomaceous earth is added, stirred, washed, and filtered; The purification includes: concentrating the filtered solution under reduced pressure at 70-80°C to less than 30% of the volume of the reaction system, then adjusting the pH of the concentrated solution to pH=1-1.5, stirring and cooling to 5-10°C, crystallizing and drying.
10. The method according to claim 7, characterized in that The preparation method of the nitrilase mutant comprises: connecting the nucleotide sequence of the nitrilase mutant to an expression vector, then introducing the obtained recombinant vector into a starting strain to obtain a recombinant bacterium expressing the nitrilase mutant, and then inoculating the recombinant bacterium into a culture medium for cultivation and induction, and then crushing and separating to obtain the nitrilase mutant.
